LON:CIR - Circassia Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 25.50 -0.80 (-3.04 %)
(As of 05/24/2019 04:00 PM ET)
Previous CloseGBX 25.50
Today's RangeGBX 25.30 - GBX 26.40
52-Week RangeGBX 25 - GBX 98.30
Volume924,716 shs
Average VolumeN/A
Market Capitalization£95.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.

Receive CIR News and Ratings via Email

Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone44 1865 405 560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£48.30 million
Cash FlowGBX 11.05 per share
Book ValueGBX 35.40 per share

Profitability

Miscellaneous

Employees400
Market Cap£95.48 million
Next Earnings DateN/A
OptionableOptionable

Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions

What is Circassia Pharmaceuticals' stock symbol?

Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR."

What price target have analysts set for CIR?

3 brokers have issued twelve-month price targets for Circassia Pharmaceuticals' stock. Their predictions range from GBX 65 to GBX 110. On average, they anticipate Circassia Pharmaceuticals' share price to reach GBX 88.33 in the next twelve months. This suggests a possible upside of 246.4% from the stock's current price. View Analyst Price Targets for Circassia Pharmaceuticals.

What is the consensus analysts' recommendation for Circassia Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Circassia Pharmaceuticals.

Has Circassia Pharmaceuticals been receiving favorable news coverage?

Headlines about CIR stock have been trending positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.

Who are some of Circassia Pharmaceuticals' key competitors?

What other stocks do shareholders of Circassia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Circassia Pharmaceuticals investors own include Oxford BioMedica (OXB), ABZENA/PAR VTG FPD 0.002 (ABZA), Allena Pharmaceuticals (ALNA), Sound Energy (SOU), Ampliphi Biosciences (APHB), AstraZeneca (AZN), Cairn Energy (CNE), FirstGroup (FGP), Filtronic (FTC) and Just Eat (JE).

Who are Circassia Pharmaceuticals' key executives?

Circassia Pharmaceuticals' management team includes the folowing people:
  • Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)
  • Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)
  • Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)
  • Ms. Nina Kataria, Sr. VP Global HR
  • Mr. David L. Acheson, Sr. VP of US Commercial

How do I buy shares of Circassia Pharmaceuticals?

Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Circassia Pharmaceuticals' stock price today?

One share of CIR stock can currently be purchased for approximately GBX 25.50.

How big of a company is Circassia Pharmaceuticals?

Circassia Pharmaceuticals has a market capitalization of £95.48 million and generates £48.30 million in revenue each year. Circassia Pharmaceuticals employs 400 workers across the globe.

What is Circassia Pharmaceuticals' official website?

The official website for Circassia Pharmaceuticals is http://www.circassia.co.uk/.

How can I contact Circassia Pharmaceuticals?

The company can be reached via phone at 44 1865 405 560.


MarketBeat Community Rating for Circassia Pharmaceuticals (LON CIR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel